Taysha Gene Therapies announced the completion of dosing in its pivotal Rett syndrome trials with a 100% responder rate [1].
This milestone moves the company closer to a potential Biologics License Application for TSHA-102, a gene therapy targeting a rare genetic disorder. Success in these trials could provide a new treatment option for patients with Rett syndrome, who currently face limited therapeutic choices.
During a recorded conference call on Tuesday, CEO and Chairman Sean Nolan said the company has achieved "the completion of dosing in both the REVEAL pivotal and ASPIRE trials" [5]. Nolan said these steps represent critical progress "toward a potential BLA submission for TSHA-102" [5].
The company also disclosed its financial results for the second quarter of 2026. Taysha reported a net loss of $46.6 million, which equates to $0.13 per share [4].
Research and development expenses for the quarter totaled $38.6 million [2]. General and administrative expenses were $12.1 million [3]. These costs reflect the intensive resource requirements of advancing pivotal clinical trials toward regulatory approval.
Taysha is now preparing for the next phase of clinical analysis. The company expects to reveal a six-month interim analysis and receive feedback from the FDA in the first half of 2027 [5].
“Taysha reported a 100% responder rate in TSHA-102 dosing.”
The completion of dosing in both the REVEAL and ASPIRE trials marks a transition from the treatment phase to the data-collection phase. While the 100% responder rate is a positive early indicator, the company's high quarterly burn rate—driven by $38.6 million in R&D—underscores the financial risk inherent in gene therapy development. The critical window for the company's valuation now shifts to the first half of 2027, when FDA feedback and interim analysis will determine if the therapy is viable for commercial submission.
